Nordea Investment Management
BTAI icon

Nordea Investment Management’s BioXcel Therapeutics BTAI Stock Holding History

Nordea Investment Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6
Closed -$1K – 1021
2019
Q1 		$1K Buy
+6
New +$740 ﹤0.01% 1292

Other funds holding BTAI

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nordea Investment Management's BTAI Position: Q2 2019 in Review

Nordea Investment Management sold out of BioXcel Therapeutics (BTAI) in Q2 2019, closing a stake of 6 shares — an estimated $1K sold.

Nordea Investment Management first reported a position in BTAI in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 36 funds tracked by Wall St. Rank hold BTAI as of Q2 2019.

  • Nordea Investment Management reported no remaining BioXcel Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Nordea Investment Management sold 6 BioXcel Therapeutics shares in Q2 2019, an estimated $1K.
  • Nordea Investment Management first reported a position in BioXcel Therapeutics in Q1 2019 and held it in 1 quarter.
  • Nordea Investment Management's BioXcel Therapeutics position peaked at $1K in Q1 2019.
  • 36 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2019.

Based on Nordea Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.